The Centers for Disease Control and Prevention estimates that the total economic burden of prescription opioid misuse alone in the United States is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement.1
Oxycodone is a semisynthetic opioid analgesic prescribed for the relief of moderate to severe pain. Oxycodone structurally resembles codeine and morphine, with similar analgesic properties and potential for addiction and abuse. Oxycodone is a DEA schedule II drug. The drug oxycodone is prescribed in controlled-release form (OXYCONTIN), or in combination with acetaminophen (PERCOCET) or with aspirin (PERCODAN).
Features & Benefits
The Emit II Plus Oxycodone assay offers 100 ng/mL and 300 ng/mL cutoffs and no cross-reactivity to structurally related compounds such as buprenorphine and hydrocodone.
Achieve high specificity for oxycodone and oxymorphone to provide confidence for accurate results while meeting the SAMHSA requirements for oxycodone screening
Reduce false results with an assay that has 98% agreement to LC-MS/MS for positive samples and 100% agreement for negatives.1
Consolidate opioid testing with other Siemens Healthineers assays, enabling providers to screen patients on one trusted system
Technical Specifications
EMIT II Plus Oxycodone Assay Performance*
Assay Principle
Homogeneous enzyme immunoassay
Assay Range
50—400 ng/mL (100 ng/mL cutoff)
75—1000 ng/mL (300 ng/mL cutoff)
Reagent Stability
Stable unopened or opened until exp., when stored refrigerated at 2–8°C
Cutoff Level
100 ng/mL and 300 ng/mL
Calibration Range
0—1000 ng/mL